“We [found] that patients' overall [total] bowel symptoms scores were improved for those of the patients who received the active therapeutic treatment of [darolutamide] versus placebo,” says Neal D. Shore, MD, FACS.
In this video, Neal D. Shore, MD, FACS, discusses the background and findings of the study, “Impact of darolutamide on local symptoms in patients with nonmetastatic castration-resistant prostate cancer,” presented recently at the 2021 American Urological Association annual meeting. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.